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The symposium on M. pneumoniae respiratory disease has examined the clinical expression
of infection in adults and children, the pathophysiologic disturbances which occur, and the
laboratory diagnosis by isolation and serology. That these infections are very common has
been well documented; however, a variable incidence over periods of several years tends to
minimize importance of the disease for many clinicians. While good laboratory diagnostic
methods exist, they provide retrospective insight predominantly and are not useful for early
diagnosis or therapeutic decision making. Development ofrapid diagnostic methods which are
sensitive and specific is an important goal for future research. Success would facilitate our
understanding and control of M. pneumoniae disease.
The importance of Mycoplasma pneumoniae as a cause of human respiratory
disease has been well documented by epidemiologic studies in various settings in
many countries [1]. In a metropolitan survey, the occurrence of mycoplasma
pneumonia varied from 0.5-2.6/1,000 population/year, depending upon the age
groups involved [21; relative to the total occurrence of pneumonia in the same
population, M. pneumoniae was responsible for between 5.7 and 28.4 percent of all
cases. As shown in Table 1, it can be estimated from other studies that the syndrome
of tracheobronchitis is 23 times more frequent than is pneumonia, and that 20 per-
cent of the mycoplasma infections are asymptomatic. Extrapolated to the present
population of the United States, these data would indicate that there are 500,000
cases of pneumonia and 11,500,000 cases of tracheobronchitis within a total of
15,000,000 infections by M. pneumoniae annually!
Despite the presence of data from surveillance and family studies indicating the
high frequency ofM. pneumoniae infections, clinicians diagnose the disease only oc-
casionally, especially those with hospital-based medical practices. There are many
reasons for this discrepancy. The mild nature of many cases does not compel pa-
tients to seek medical attention; those who report are seen most often in ambulatory
primary care facilities where their symptoms and signs are so non-specific that M.
pneumoniae is not considered and only symptomatic treatment is prescribed. Cases
recognized during the occurrence of epidemic peaks tend to be forgotten during the
next few years when only endemic disease occurs.
As indicated before, the most freqhent clinical presentation ofM. pneumoniae in-
fection is the syndrome of tracheobronchitis associated with an influenza-like ill-
ness. This type ofillness is a rather nondescript clinical entity which includes a cough
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TABLE 1
Mycoplasma pneumoniae in the United States
Syndrome Incidence/year, Total Casesb
Pneumonia 2/1,000' 500,000
Tracheobronchitis 46/1,0002 11,500,000
Asymptomatic infections 12/1,0003 3,000,000
All Infections 15,000,000
aExtrapolations based on:
'Alexander, et al: New Eng J Med 275:131, 1966
2Chanock, et al: JAMA 175:213, 1961
3Foy, et al: JAMA 197:137, 1966
bEstimated census of 250 million
together with other evidence of respiratory tract infection, such as fever, malaise,
rhinorrhea, pharyngitis, sinusitis, and otitis media. One study in a pediatric practice
population revealed the most common etiologic agents of tracheobronchitis to be
respiratory syncytial virus, parainfluenza virus types 1 and 3, influenza viruses A and
B, and M. pneumoniae [3]. Clinical differentiation of these agents was not possible
except through consideration of epidemiologic features, particularly age of the pa-
tient and seasonal occurrence: most patients were older than four years, and out-
breaks usually occurred between July and January. In this type of disease M.
pneumoniae might be suspected if a concurrent epidemic were known, or if M.
pneumoniae pneumonia had been diagnosed in a household contact of the patient
with tracheobronchitis.
In patients presenting with pneumonia, as evidenced by pulmonary rales or
dullness or by chest X-ray abnormalities, M. pneumoniae always should be con-
sidered among the etiologic possibilities because of its major contribution to the
causation of pneumonia. Clinicians often think of conventional bacterial infections
first in patients with pneumonia, probably because of the life-threatening conse-
quences of these infections. Viral or mycoplasmal pneumonia may be considered
secondarily and usually after efforts to exclude bacterial disease. Since it has been
shown that viral and mycoplasmal pneumonias are indistinguishable by clinical and
radiographic features [4], the practitioner is left with few valid criteria on which to
base a primary diagnosis of mycoplasmal disease.
From the foregoing it is apparent that the diagnosis of M. pneumoniae disease
may present a difficult problem for the practitioner. The following points, based on
the state of knowledge which has been reviewed in this symposium, are suggested as
guides (Table 2).
1. M. pneumoniae should be considered in all cases of pneumonia, since it is one
of the more common etiologic agents. The frequency of mycoplasma pneumonia
rivals the estimated occurrence of Streptococcus pneumoniae disease, which is the
other common cause. Certain clinical characteristics make the likelihood of M.
pneumoniae greater, including: patients of elementary school age, adolescents, or
young adults; epidemics within families; and epidemics occurring outside the usual
respiratory disease season, as in the summer and fall months. The disease has a very
high incidence in closed population groups such as military recruits and university
students [1].
2. The general clinical syndrome of M. pneumoniae disease is an influenza-likeMYCOPLASMA PNEUMONIAE SYMPOSIUM
TABLE 2
Diagnosis of Mycoplasma pneumoniae Disease
1. Consider in all cases of pneumonia
2. "Flu-like" febrile illness of gradual onset
3. Symptoms of acute tracheobronchitis
4. Paucity of physical findings
5. Chest X-ray
6. Exclude bacterial disease
7. Cold hemagglutinin test
8. Mycoplasma culture
9. Mycoplasma serology
illness with components of low-grade fever, headache, and lassitude. In true in-
fluenza disease the symptomatology develops rapidly, usually within 24 hours; in
mycoplasmal disease the systemic manifestations develop more gradually over a
period of several days. Many patients will have been symptomatic up to one week
before seeking medical attention.
3. In addition to the systemic elements ofillness, cough indicating the presence of
tracheobronchitis is seen in most if not all M. pneumoniae infections. Initially the
cough is dry, but later becomes productive of mucoid or muco-purulent sputum.
Coughing may occur in paroxysms and often is worse in the evening, disturbing
sleep.
4. M. pneumoniae disease often is accompanied by few physical signs, and the
patients' complaints seem disproportionate to the observable evidence of infection.
There may be slight erythema of the pharynx associated with complaint of a dry or
scratchy sore throat. Rhonchi may be palpated or auscultated in the chest if sputum
is being produced. The presence of rales, especially at the end of deep inspiration,
should be sought with care since this finding would suggest pneumonia in this set-
ting. Rarely are there sufficiently large areas of atelectasis or of pleural effusion to
allow detection by physical examination.
Two other clinical syndromes should suggest the diagnosis of M. pneumoniae
disease: the first is bullous myringitis, a painful red vesicular lesion of the tympanic
membrane; the second is erythema multiforme exudativum (Stevens-Johnson syn-
drome) which involves both skin and mucus membranes. Neither bullous myringitis
nor Stevens-Johnson syndrome occur exclusively with mycoplasma disease, but the
diagnostic possibility is suggested by the numerous reports of these associations. No
estimate of the incidence of these manifestions is available.
5. The chest X-ray is a very useful adjunct to the diagnosis of M. pneumoniae
pneumonia, because of the limited physical findings outlined in item 4. Changes
may precede the appearance of signs involving the lungs. The usual manifestations
are increased peribronchial markings, generally involving one of the lower lobes.
Associated perihilar streaking indicative of interstitial infiltration and areas of sub-
segmental atelectasis may be seen. Small, often transient collections of pleural fluid
are not unusual. Emphasis has been placed on the most common X-ray presenta-
tion, but it should be mentioned that changes which mimic many other pulmonary
disease processes can be encountered, making the diagnosis more obscure in some
cases.
6. Once the diagnosis of M. pneumoniae disease is entertained, it can be
strengthened by steps to exclude other possibilities. Useful aids are the peripheral
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blood total and differential leukocyte counts which usually are normal; typically
leukopenia occurs in viral syndromes, and leukocytosis in classical bacterial
pneumonias. An exception may occur in patients with sickle cell disease, who have
been reported to develop polymorphonuclear leukocytosis during mycoplasma
pneumonia [5]. Bacterial cultures of peripheral blood or buffy coat may be helpful
to exclude sepsis which can be secondary to bacterial pneumonia. Careful collection
of historical information may remove some entities from the differential diagnostic
list, for example, psittacosis, mycoses, tuberculosis, aspiration pneumonitis, and oc-
cupational lung disease.
7. A simple diagnostic procedure with may be helpful is the cold hemagglutinin
test. These temperature-dependent agglutinins are present in about half of patients
with M. pneumoniae pneumonia, developing late in the first or during the second
week of symptoms and increasing fourfold or more in titer by the third week. The
IgM-anti-I antigen antibodies which are responsible for the agglutination disappear
in about six weeks. Because of their early appearance, cold hemagglutinins may be
found when patients are first seen, and can be helpful for therapeutic decisions.
High titers(2 1:128) and fourfold rises (or falls) in titers between paired sera suggest
M. pneumoniae infection. However, the reaction is not specific for mycoplasma
disease since cold hemagglutinins occur in a variety of other conditions. If the reac-
tion is negative, M. pneumoniae disease is not excluded. There are correlations be-
tween severity of pneumonia and higher cold hemagglutinin titers; antibiotic therapy
tends to suppress the response.
A screening, or "bedside" cold hemagglutinin test is very useful clinically. As
originally described [6], 0.2 ml patient blood is mixed with an equal volume of Na
citrate solution in a small tube which is iced for 15 seconds. The tube is then tipped
and rotated for inspection of the blood film. A positive test is indicated by floccular
agglutination which disappears when the tube is warmed to37°C. Quantitative
studies have shown that a positive test indicates a standard method titer 2 1:64 [7].
8. The "gold standard" for diagnosis of mycoplasma pneumonia remains isola-
tion of M. pneumoniae from sputum or respiratory tract secretions. Dr. Tully has
provided evidence that the SP-4 formula first used to isolate Spiroplasma mirum [8]
is a superior medium for recovering M. pneumoniae compared with earlier formula-
tions. Development of improved media should augment our diagnostic ability. Un-
fortunately, isolation information is useful mainly in retrospect since time required
(seven days-six weeks) is too long to assist therapeutic decisions.
9. Serological methods have been the most popular form of diagnosis for M.
pneumoniae infections in recent years; necessary reagents have become commer-
cially available, and few laboratories have the capability for isolation and identifica-
tion procedures. The complement fixation method has enjoyed greatest use,
although the specificity of the reaction is being questioned since the antigens in-
volved are not unique to M. pneumoniae. Diagnostic results require comparisons of
titers in acute and convalescent sera, making this another retrospective method. Due
to the ubiquity of M. pneumoniae infections, measurable antibodies in single sera
can indicate either current or prior infection and thus are not diagnostic. As dis-
cussed by Drs. Busulo and Meloni, use of newer techniques such as ELISA has merit
in providing greater specificity and rapidity for sero-diagnosis. The measurement of
M. pneumoniae specific IgM antibodies, as permitted by ELISA, also suggests ac-
tive infection as opposed to IgG antibodies which may persist for a long time follow-
ing infection.
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From this review ofour ability to recognize M. pneumoniae disease clinically, and
to diagnose it in the laboratory, it becomes apparent that a major shortcoming is the
lack of a sensitive and specific rapid diagnostic test. Many years ago Hers [9]
described success using immunofluorescence with sputum samples, but no reports
have appeared of the systematic application of this approach. The method could be
difficult to apply to children who rarely are able to provide sputum specimens. As
pointed out in a recent letter by Drs. Foy and Allan, "The most cogent reason for
failure to recognize the importance ofthis agent is the lack ofa rapid diagnostic test"
[10]. If a simple procedure were available for clinical use, the many infections which
masquerade as "non-specific tracheobronchitis" or as "viral syndrome" could be
recognized and treated more effectively. Furthermore, increased recognition of in-
fections can expand our understanding of the clinical features of the disease which
were addressed earlier in detail by Drs. Niitu and Izumikawa. This in turn will
facilitate greater understanding ofthe pathogenesis, including the clinical expression
of the pathophysiologic disturbances which have been described by Dr. Yoshida.
This symposium has served to provide a forum for discussion of many implications
for the future concerning an important human respiratory disease.
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